With 7,000 employees in 25 locations across 12 countries in the region, PAREXEL now has more than a third of its global staff in Asia Pacific (APAC). Albert Liou, Vice Chairman, Asia Pacific, PAREXEL, discusses the biotech momentum that has been boosting the attractiveness of the region in terms of new drug development activities. He also provides insights into the company’s unique contribution to the R&D-driven ecosystem in Taiwan, where the global clinical research organization (CRO) also has its regional headquarters.
As Vice Chairman, Asia Pacific for PAREXEL, what would you highlight as the most impactful trends occurring in the region when it comes to drug development?
"In Taiwan, one of our most valuable differentiators is our strong commitment to further enhancing the country’s R&D ecosystem by operating as a knowledge and expertise center."
